Background The cell and gene therapy (CGT) field is at a critical juncture. Clinical successes
have underpinned the requirement for developing manufacturing capacity suited to patient …

Decentralised or 'redistributed'manufacturing represents an attractive choice for production
of some cell and gene therapies (CGTs), in particular personalised therapies. Decentralised …

Decentralized or “redistributed” manufacturing has the potential to revolutionize the
manufacturing approach for cell and gene therapies (CGTs), moving away from the “Fordist” …

Background aims Cell-based therapies (CBTs) provide opportunities to treat rare and high-
burden diseases. Manufacturing development of these innovative products is said to be …

Aim: Manufacturing methods for cell-based therapies differ markedly from those established
for noncellular pharmaceuticals and biologics. Attempts to 'shoehorn'these into existing …

Cell and gene therapy products are rapidly being integrated into mainstream medicine.
Developing global capability will facilitate broad access to these novel therapeutics. An …

Background aims Recent technical and clinical advances with cell-based therapies (CBTs)
hold great promise in the treatment of patients with rare diseases and those with high unmet …

Manufacturing of more-than-minimally manipulated autologous cell therapies presents a
number of unique challenges driven by complex supply logistics and the need to scale out …

The choice of manufacturing strategy for cell-based therapeutics is one that is best made
early in product development. Expense and delay may result from any additional bridging …

Exciting developments in the cell therapy field over the last decades have led to an
increasing number of clinical trials and the first cell products receiving marketing …